You are here

  • Home
  • Archive
  • Volume 8, Issue Suppl 3
  • 442 ICT01, an anti-BTN3A mAb that activates Vg9Vd2 T cells, plus interleukin-2: a potent and promising combination for cancer immunotherapy

Article metrics

Article menu

Download PDFPDF

Regular and young investigator award abstracts
Combination immunotherapies
442 ICT01, an anti-BTN3A mAb that activates Vg9Vd2 T cells, plus interleukin-2: a potent and promising combination for cancer immunotherapy

 

Online download statistics by month:

Online download statistics by month: November 2020 to June 2025

AbstractFullPdf
Nov 2020117016
Dec 20202806
Jan 20212202
Feb 20212703
Mar 20214807
Apr 20214607
May 20218010
Jun 20210012
Jul 20210011
Aug 20211015
Sep 20210011
Oct 202162031
Nov 202118018
Dec 20211603
Jan 20223003
Feb 20221403
Mar 20223605
Apr 20224007
May 20224403
Jun 20221602
Jul 20221001
Aug 20221302
Sep 20221001
Oct 2022800
Nov 20221402
Dec 20221801
Jan 20232004
Feb 20231600
Mar 20231000
Apr 20232005
May 20231605
Jun 20231202
Jul 20231404
Aug 20231002
Sep 20231201
Oct 20231003
Nov 20232805
Dec 20238804
Jan 20242401
Feb 20243000
Mar 20242401
Apr 20241201
May 20242001
Jun 20242401
Jul 20241802
Aug 20241401
Sep 20242602
Oct 20243607
Nov 202440013
Dec 202424012
Jan 2025804
Feb 2025403
Mar 2025007
Apr 2025003
May 2025008
Jun 2025006
Total12060290